InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.62
(
-0.16%
)
US TECH 100
19,220.00
(
-0.20%
)
Dow Jones
39,150.33
(
0.04%
)
Brent Oil
84.31
(
0.34%
)
Bitcoin
62,840.88
(
-0.50%
)
Post# of 252311
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

rfj1862

Send PM Follow Ignore
Followers 39
Posts 1714
Boards Moderated 0
Alias Born 10/05/2005

rfj1862

Re: DewDiligence post# 49194

Monday, 07/02/2007 4:21:43 PM

Monday, July 02, 2007 4:21:43 PM

Post# of 252311
MDCO

This could represent a great opportunity. Both cleviprex and cangrelor are in the pipeline and represent relatively low-risk opportunities.

The issue in Europe, as I understand it, isn't the premium price, it's the crappy job Nicomed has done promoting the drug. Given MDCO's expertise in marketing, I'm sure they'll be able to ramp up Angiomax sales in Europe.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up